Capital International Inc. CA Has $1.39 Million Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Capital International Inc. CA cut its holdings in Grifols, S.A. (NASDAQ:GRFS) by 4.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 186,834 shares of the biotechnology company’s stock after selling 8,737 shares during the period. Capital International Inc. CA’s holdings in Grifols were worth $1,390,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Capital World Investors grew its position in shares of Grifols by 0.7% during the 4th quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company’s stock worth $157,239,000 after purchasing an additional 154,358 shares in the last quarter. First Trust Advisors LP acquired a new position in Grifols in the 4th quarter valued at $75,000. Capital International Sarl lifted its position in shares of Grifols by 5.4% during the 4th quarter. Capital International Sarl now owns 544,829 shares of the biotechnology company’s stock valued at $4,054,000 after acquiring an additional 27,715 shares during the period. Mariner LLC grew its holdings in shares of Grifols by 382.4% during the 4th quarter. Mariner LLC now owns 119,472 shares of the biotechnology company’s stock worth $889,000 after purchasing an additional 94,706 shares in the last quarter. Finally, Black Creek Investment Management Inc. increased its position in shares of Grifols by 1.3% in the fourth quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company’s stock worth $83,715,000 after purchasing an additional 141,615 shares during the period.

Analyst Ratings Changes

Separately, Morgan Stanley began coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Stock Up 0.7 %

Shares of NASDAQ GRFS opened at $7.08 on Monday. The company has a market cap of $4.87 billion, a price-to-earnings ratio of 6.05 and a beta of 0.41. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12 month low of $5.79 and a 12 month high of $9.96. The stock has a 50-day moving average price of $7.49 and a two-hundred day moving average price of $7.80.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.